No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients
Abstract There are contrasting findings regarding the effect of HIV on the pharmacokinetics of first‐line anti‐tubercular drugs (FLATDs) due to a lack of prospective controlled clinical studies, including patients with tuberculosis (TB) and patients with TB living with HIV. This study aims to assess...
Saved in:
Main Authors: | Glauco Henrique Balthazar Nardotto (Author), Valdes Roberto Bollela (Author), Adriana Rocha (Author), Oscar Della Pasqua (Author), Vera Lucia Lanchote (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of Interindividual Variability in Metabolic Clearance and Relative Bioavailability on Rifampicin Exposure in Tuberculosis Patients with and without HIV Co-Infection: Does Formulation Quality Matter?
by: Glauco Henrique Balthazar Nardotto, et al.
Published: (2024) -
Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of <i>Mycobacterium tuberculosis</i> Infection
by: Laura Sibley, et al.
Published: (2022) -
Immune reconstitution inflammatory syndrome following treatment of cutaneous tuberculosis with rifampin, isoniazid, pyrazinamide, and ethambutol
by: Ralina Karagenova, MS, et al.
Published: (2024) -
C-1 Substituted isoquinolines potentiate the antimycobacterial activity of rifampicin and ethambutol
by: Liam T. Martin, et al.
Published: (2023) -
The effect of noni fruit (Morinda citrifolia L.) extract on interleukin 4 and interleukin 10 in Wistar rats, induced by pyrazinamide, ethambutol and levofloxacin
by: Thontowi Djauhari Nur Subchi, et al.
Published: (2019)